An emerging technique for the dual‑targeting chemo‑radio‑ablation of generic micro‑cancers in conjunction with cancer liquid biopsy

Ni,Yicheng

doi:10.3892/or.2022.8472

An emerging technique for the dual‑targeting chemo‑radio‑ablation of generic micro‑cancers in conjunction with cancer liquid biopsy

Authors:
- Yicheng Ni
View Affiliations

Affiliations: Theragnostic Laboratory, Department of Imaging and Pathology, Faculty of Medicine, Biomedical Group, KU Leuven, 3000 Leuven, Belgium
Published online on: December 23, 2022 https://doi.org/10.3892/or.2022.8472
Article Number: 35

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer liquid biopsy (CLB) aims for the detection of circulating tumor cells, cell‑free DNA or RNA, and specifically expressed proteins, lipids and metabolites present in the bio‑fluids of patients. Rapid advances in technologies for sampling such bio‑specimens and for genomic sequencing have fostered the development of authority‑approved CLB tests in clinical practice for the early screening and diagnosis of malignancies. However, perhaps some solid tumors could have been reliably detected using CLB, while they were still too small to be found in patients using currently available imaging technologies. This could impose troublesome clinical scenarios. In this communication article, the author would like to propose a potential solution that eventually may be used to combat such unwanted embarrassing clinical issues by using one episode of targeted radiotheragnostics, namely OncoCiDia.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
2	Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, Queiroz MA, Cerri GG and Buchpiguel CA: Theranostics in nuclear medicine: Emerging and Re-emerging integrated imaging and therapies in the era of precision oncology. Radiographics. 40:1715–1740. 2020. View Article : Google Scholar : PubMed/NCBI
3	Frangos S and Buscombe JR: Why should we be concerned about a ‘g’? Eur J Nucl Med Mol Imaging. 46:5192019. View Article : Google Scholar : PubMed/NCBI
4	Pinzani P, D'Argenio V, Del Re M, Pellegrini C, Cucchiara F, Salvianti F and Galbiati S: Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med. 59:1181–120. 2021. View Article : Google Scholar : PubMed/NCBI
5	Crosby D: Delivering on the promise of early detection with liquid biopsies. Br J Cancer. 126:313–315. 2022. View Article : Google Scholar : PubMed/NCBI
6	Cona MM, Oyen R and Ni Y: Necrosis avidity of organic compounds: A natural phenomenon with exploitable theragnostic potentials. Curr Med Chem. 22:1829–1849. 2015. View Article : Google Scholar : PubMed/NCBI
7	Li J, Sun Z, Zhang J, Shao H, Cona MM, Wang H, Marysael T, Chen F, Prinsen K, Zhou L, et al: A dual targeting anticancer approach: Soil and seed principle. Radiology. 260:799–807. 2011. View Article : Google Scholar : PubMed/NCBI
8	Ni Y: Oncocidia: A small molecule dual targeting pan-anticancer theragnostic strategy. Cancer Res. 74:17672014. View Article : Google Scholar
9	Siemann DW, Chaplin DJ and Walicke PA: A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs. 18:189–197. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM and Bormans GM: First preclinical evaluation of mono-[123I]iodohypericin as a necrosis avid tracer agent. Eur J Nucl Med Mol. 33:595–601. 2006. View Article : Google Scholar : PubMed/NCBI
11	Cona MM, Feng YB, Verbruggen A, Oyen R and Ni Y: Improve clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats. Exp Biol Med (Maywood). 238:1437–1449. 2013. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Jiang C, Jiang X, Sun Z, Cona MM, Liu W, Zhang J and Ni Y: Biliary and duodenal drainage for reducing the radiotoxic risk of antineoplastic ¹³¹I-hypericin in rat models. Exp Biol Med (Maywood). 240:1764–1773. 2015. View Article : Google Scholar : PubMed/NCBI
13	Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K and Luster M: Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: A review of the literature of the past decade. Eur J Nucl Med Mol Imaging. 47:78–83. 2020. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Yin T, De Keyzer F, Feng YB, Chen F, Liu JJ, Song SL, Yu J, Vandecaveye V, Swinnen J, et al: Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. Oncotarget. 8:55204–55215. 2017. View Article : Google Scholar : PubMed/NCBI
15	Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y and Ni Y: A review on curability of cancers: More efforts for novel therapeutic options are needed. Cancers (Basel). 11:17822019. View Article : Google Scholar : PubMed/NCBI
16	Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J and Kabbinavar F: A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Onco Targets Ther. 9:7275–7283. 2016. View Article : Google Scholar : PubMed/NCBI
17	Folkman J, Long DM Jr and Becker FF: Growth and metastasis of tumor in organ culture. Cancer. 16:453–467. 1963. View Article : Google Scholar : PubMed/NCBI
18	Sugimoto K, Kim SR, Imoto S, Tohyama M, Kim SK, Matsuoka T, Yano Y, Kudo M and Hayashi Y: Characteristics of hypo-vascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2 cm-focus on tumor size, markers and imaging detectability. Dig Dis. 33:721–727. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hori K, Nishihara M, Shiraishi K and Yokoyama M: The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors. J Pharm Sci. 99:2914–2925. 2010. View Article : Google Scholar : PubMed/NCBI
20	Maeda H: Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 88:53–71. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ni Y: Treatment of avascular or hypovascular micro-tumors. US Patent 16/628,904, Filed. July 4–2018 issued. January 10–2019.
22	Cacho-Díaz B, García-Botello DR, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sánchez E and Herrera-Montalvo LA: Tumor microenvironment differences between primary tumor and brain metastases. J Transl Med. 18:12020. View Article : Google Scholar : PubMed/NCBI
23	Osako T: How can we better distinguish metastatic tumors from primary tumors in the breast? Expert Rev Anticancer Ther. 21:913–916. 2021. View Article : Google Scholar : PubMed/NCBI
24	Kim R, Keam B, Kim S, Kim M, Kim SH, Kim JW, Kim YJ, Kim TM, Jeon YK, Kim DW, et al: Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors. BMC Cancer. 19:192021. View Article : Google Scholar : PubMed/NCBI
25	Ikarashi D, Okimoto T, Shukuya T, Onagi H, Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S and Carbone DP: Comparison of tumor microenvironments between primary tumors and brain metastases in patients with NSCLC. JTO Clin Res Rep. 2:1002302021.PubMed/NCBI
26	Pearce OM, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, et al: Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Dis. 8:304–319. 2018. View Article : Google Scholar : PubMed/NCBI